User login
Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).
Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.
Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.
Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.
Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946
Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).
Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.
Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.
Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.
Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946
Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).
Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.
Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.
Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.
Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946